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Aspects of Insulin Treatment
ZACHARY T. BLOOMGARDEN, MD
T
hisisthesecondofaseriesofarticles
based on presentations at the Amer-
ican Diabetes Association Scientiﬁc
Sessions held 5–9 June 2009 in New Or-
leans, Louisiana, pertaining to insulin
treatment approaches. At a symposium
on aspects of continuous subcutaneous
insulin infusion (CSII) treatment, Nancy
Bohanon (San Francisco, CA) discussed
new approaches to make this treatment
available for subjects with type 2 diabetes
and pointed out that “the pumps work!”
She predicted that several of these prod-
ucts might be available within the next
year.
Patch pumps
The Valeritas h-Patch technology has
beenusedtodevelopaV-Goinsulinpatch
pump (www.valeritas.com) to deliver
both basal and bolus insulin, requiring a
ﬁxed basal dose, which appears to be pre-
set to rates of 20, 30, and 40 units per
24 h. For bolus delivery, each click deliv-
ers 2 units up to a total of 36 units per
24 h. The pump is worn for 24 h, ﬁlled
with an external device, with the backing
removed to adhere to the skin. A button
on the pump is pressed to insert a 30G
needle. Bolus doses are delivered by
pressingabuttonononesidethatreleases
a bolus delivery deployment button—a
safety feature to prevent accidental bolus
delivery. After 24 h, a button is pressed to
withdrawtheneedle.Thedeviceispurely
mechanical, does not require a battery-
driven pump or external controller, ﬁts
under clothing, and can be operated
through clothing. In a user-preference
program, patients liked it and considered
it to be easy to use, discrete, and comfort-
able, although the ﬁlling mechanism was
not considered to be ideal. Common to a
number of these devices, although pre-
sumably allowing a less complex delivery
mechanism, the single preset basal rate is
somewhat disadvantageous, as an impor-
tantbeneﬁtofCSIIbasalratesistheability
to deliver more and less insulin during
periods of lesser and greater insulin sen-
sitivity, given the exaggerated diurnal
rhythm of insulin sensitivity characteris-
tic of many type 2 diabetic patients. A re-
port of use of the V-Go for 7 days in six
patients previously receiving insulin
glargine showed comparable glycemic
control with signiﬁcantly lower levels at
bedtime and 3:00 A.M. (1).
Finesse (Calibra Medical) is another
mechanical (nonelectrical) pump, with a
reservoir containing up to 200 units, de-
signed with two buttons, one on each
side, with a double “squeeze” providing a
ﬁxed dose; different models deliver 1⁄2,1 ,
2, or 5 units per squeeze. The unit is thin,
with an external disposable cannula. It
adheres to the body and can be operated
throughclothing,lastingupto3days.Al-
though the device does not deliver basal
insulin, given the lack of adjustable basal
dosesintheotherdevices,thismaynotbe
a complete negative, and it can be used to
deliver bolus insulin or pramlintide—
another potential advantage.
The Medingo Solo patch pump is
electronicwithamatchboxsizepatchand
an external electronic controller, but it
also has a button on the patch allowing
bolusestobedeliveredmanually.Thisisa
full-featured insulin pump, with variable
basalrates,allowingdeliveryofbolusesin
standard, dual-wave, and square-wave
forms. The MedSolve Technologies Free-
handpumpisdesignedforuseinsubjects
with both type 1 and type 2 diabetes; it is
considerably smaller than currently avail-
able devices, with a remote controller, al-
lowing multiple basal rates as well as
delivering small bolus increments. Other
very small insulin pumps in development
are an insulin pump from Cellnovo, a
Welsh company using microﬂuidics for
insulin delivery; a patch pump from Star-
bridgeSystems;theNiliMEDIXsingle-use
disposable pump, which may incorporate
a continuous glucose monitoring (CGM)
sensor; and the STMicroelectronics and
Debiotech insulin nanopump using a patch
system and a separate electronic controller,
smaller than traditional pumps and with a
large insulin reservoir. Medtronic also may
be developing a patch delivery system,
controlled both with a remote unit and
withmanualbolusdeliverybybuttonson
the device.
Another approach to basal insulin
delivery being developed by Altea Thera-
peutics is the PassPort transdermal insu-
lin patch, lasting either 12 or 24 h to
provide constant basal insulin. This com-
pany is also developing a transdermal ex-
enatide preparation, and devices are
being developed for delivery of glucagon-
like peptide-1 and pramlintide as well as
insulin.
Approaches to CSII
ChrisSadler(LaJolla,CA)gaveanupdate
on CSII technology, emphasizing “con-
vergence [and] connectivity with other
devices” and new design aspects of exist-
ing and planned pumps from Animas, In-
sulet, Roche, and Medtronic. These
devicesmayallowmorepreciseandphys-
iological insulin delivery, decreased glu-
cose ﬂuctuations and variability, lower
risk of hypoglycemia, particularly during
the night, and greater ability to handle
dawn phenomenon and stress periods of
increased insulin requirement. The de-
vicesalsouse“smartfeatures”toeliminate
stacking where insulin doses are admin-
istered without taking into account resid-
ual insulin delivered in previous boluses.
Ease of use features in the newer de-
vices will include reminders to check glu-
coselevels,tochangeinfusionsets,andto
alarm for low insulin reservoir content.
Other important features of new pumps
will be improved screens with higher
graphic resolution, allowing easier pro-
gramming; more comfortable infusion
sets, allowing oblique and perpendicular
insertions;andquick-releaseinfusionsets
to shower, swim, or change clothing. Au-
to-inserters being developed will allow
more rapid and accurate insertion with-
out crimping of the cannula and reducing
“needlephobia”forchildren.Tactilefeed-
back after delivery of insulin boluses and
external controllers that allow pumps, par-
ticularlythe“tubeless”patchpumps,tostay
hidden will further improve ease of use.
Physiological features of CSII include
multiple basal rates, as low as 0.025
units/h, particularly important in pediat-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is afﬁliated with
the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York.
DOI: 10.2337/dc10-zb01
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
Reviews/Commentaries/ADA Statements
PERSPECTIVES ON THE NEWS
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 e1rics and for very insulin-sensitive adults,
square and combination bolus features,
and the calculation of suggested bolus
based on glucose, insulin-carbohydrate
ratios, glucose correction factors, dura-
tion of insulin action factors, and occlu-
sionandsafetyalarms.Sadlerpointedout
that it is possible, unfortunately, to “out-
smart a smart pump” and that patients
need to use the bolus calculators to fully
beneﬁtfromthesedevices,sothattheydo
not become just “a fancy syringe.” To use
pumps properly, then, patients must reg-
ularly test glucose levels and must accu-
rately estimate carbohydrate amounts. As
pumps cannot anticipate exercise, meals,
and stresses, it is useful for patients using
the devices to understand the use of tem-
porary basal and square- or dual-wave
features and “to plan ahead.” A further
important concept is the need to adjust
insulin treatment prospectively rather
than falling into the trap of “reacting to
numbers” with frequent between-meal
corrections and such continual adjust-
ment of basal rates that it is difﬁcult to
determine actual requirements. Clearly,
tooptimallyusethedevices,patients(and
their health care professionals) need to
regularly download and review glucose
data. Pumps capture a wealth of data, and
itisimportanttoorganizetheinformation
to allow rapid interpretation, with the
“modal day” display particularly useful.
Data analysis with artiﬁcial intelligence
software should be designed to recognize
glucose patterns and alert patients and
providers to possible need for changes in
basal or bolus doses, ideally with simpli-
ﬁed and more rapid data downloading.
Sadler noted that these approaches are
leading to “stepwise progress to ﬁnally
clos[e] the loop.”
Connectivity is another important
feature for coming CSII technologies. In
addition to the transmission of CGM and
control of insulin infusion rates by small
devices, Sleep Sentry devices with remote
display and alarms are being developed,
and a very interesting concept will be of
future connectivity to smartphones as
dataintegrators.Aserviceunderdevelop-
ment at Diasend.com promises to use cell
phonetechnologyandallowuploadingof
information from multiple meters, from
CGM, and from pump insulin dose infor-
mation to be shared by patients and
clinicians. Modiﬁed smartphones with
built-in glucose testing and pump con-
trollers are also being developed. Future
directions will include what Sadler
termed“coolfactors,”suchascoloredand
personalizedpumpcontrollersdisplaying
“skins” to allow patients to upload im-
ages. Pumps are being developed with
moreintuitiveinterfacesandscreens,per-
haps made using ﬂexible polymer devices
including a ﬂat, ﬂexible rechargeable bat-
tery allowing the pump to conform to
body shape, with low-power screens,
longer battery life, and color-coding of
CGM displays to rapidly inform the
wearer whether blood glucose levels are
stable, rising, or falling. The Charmr and
Tolea insulin pump concepts embody
some of these ideas. New infusion-sensor
combinations may allow simultaneous
continuous glucose measurement and in-
fusion of insulin along with pramlintide
and glucagon.
None of these approaches are easy for
diabetic patients. Insulin still is slow-
acting, there are still infusion site failures
and overused sites, and there is a huge
stress of constant need for troubleshoot-
ing,sensorsnotworking,theneedtowear
multiple devices and carry back-up sup-
plies,leadingforsomepatientstoanover-
whelming psychological burden. There is
also a burden for clinicians, and Sandler
touched on the question, “How do we get
paid?” Reimbursement for providers in-
volved in these time-consuming treat-
ment approaches may not be readily
available.
Closing the loop
Bruce Buckingham (Stanford, CA) dis-
cussed approaches to “closing the loop”
with CSII, a continuous glucose sensor,
and a control program. “Why,” he asked,
“aren’t we using closed loops today?” Is-
sues include the time delay of existing
glucose sensors, probably physiologically
6–7min,butincreasedto10–11mindue
to the ﬁlters in the devices, as well as the
accuracy of sensor glucose measurement.
There is biological variability in insulin
action and meal absorption, with insulin
action after a subcutaneous insulin pump
bolus taking at least 30 min to begin to
affect glucose levels, “so you’re at least a
half hour behind the curve,” although
more rapidly acting insulin preparations,
microneedles, local warming, hyaluroni-
dase, and intraperitoneal pumps may im-
prove this. Exercise is an extremely
important factor, but it has proven
difﬁcult to determine appropriate dose
change recommendations to address this.
The use of the Biostator beginning in
1976ledtointerestinthedevelopmentof
technologies that would make this degree
of precise glucose control available in
convenient, portable devices; implanted
pump studies have been carried out in
France by Renard and colleagues over the
past 2 decades furthering interest in such
approaches (2). Basal glucose control is
deﬁnitely achievable; Buckingham re-
viewed a study of 10 adults who were
usingasubcutaneouspumpwithanalgo-
rithm-basedinsulincontroller,targetinga
120 mg/dl blood glucose, and who
achieved mean fasting glucose of 125 mg/
dl, with modest advantages in overnight
glycemic stability over standard insulin
infusionprotocols,althoughnotavoiding
postmeal hyperglycemia (3). Another al-
gorithm is the “moving horizon concept,”
which uses archived measurements to
plan stepped insulin boluses, presumably
acquiring information in this fashion
about changes in the individual’s insulin
sensitivity. The most difﬁcult aspect of
closed loop insulin delivery is the meal
bolus. Buckingham reviewed the simple
observation that giving meal boluses 20
min prior to food ingestion leads to much
ﬂatter glycemic responses. In a study
comparing closed loop with hybrid con-
trol, giving bolus doses ahead of the meal
decreased postmeal peaks by 30 mg/dl
(4). This is of particular importance as
closed loop systems are hampered by the
time delay inherent in subcutaneous in-
sulin administration. In the closed loop
study, the mean glucose was 138 mg/dl,
with 85% of glucose levels in target range
(vs. 58% for the standard treatment ap-
proach). Another aspect of true artiﬁcial
pancreas systems in mimicking physio-
logical insulin patterns must be meal size
and composition estimation. Glucose
rates of change vary considerably with
different meal compositions, with the
most rapid changes after high-carbohy-
drate meals. Buckingham noted that
CGM analysis programs can be modiﬁed
todetectpresumedmeal-relatedincreases
in glucose levels brought about by omis-
sion of preprandial bolus dosing, which
could be quite useful in pediatrics to then
deliver insulin. “There’s an explosion of
studies being done,” he commented, to
detect the onset of eating and to detect
failure of either the sensor or the insulin
infusion system. Addressing physical ac-
tivity is another issue, with a study using
the Actical multidirectional piezoelectric
accelerometer to measure activity sug-
gesting an approach in modifying insulin
sensitivity. This can be more simply ac-
complished with a heart rate monitor to
judgechangesinactivity,andstudiessug-
gest this to be potentially useful as well.
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the sensors give optimal results and
whether more than one sensor should be
used at one time. Buckingham observed
that ﬂuorescent sensors appear to be an
interesting approach. Further modiﬁca-
tions of the artiﬁcial pancreas might be
the use of glucagon to provide a brake to
preventhypoglycemia,anapproachtobi-
hormonal control that has been investi-
gated in a porcine model (5), or the use of
pramlintide to delay gastric emptying.
Buckingham suggested that an approach
to the design of algorithms may be to use
“in-silico” computer modeling of type 1
diabetes rather than doing animal studies
to allow development of approaches that
would reduce glycemic variation in hu-
man studies and, ultimately, in patient
treatment.
CSII for type 2 diabetes
Bruce Bode (Atlanta, GA) discussed the
use of insulin pumps for type 2 diabetes.
There are, he stated, 5.6 million insulin-
treated diabetic individuals in the U.S., of
whom 4.5 million have type 2 diabetes.
He cited estimates that 31% of type 1 but
5% of type 2 diabetic patients use CSII
andthat71%ofpatientsonmultiple-dose
insulin (MDI) regimens do not inject in-
sulin outside the home, particularly those
with type 2 diabetes. The goal of insulin
treatment is, however, to duplicate phys-
iology; Bode argued that an insulin pump
is better than subcutaneous injections,
particularly with the technology so rap-
idly changing to improve usability. CSII
will, Bode stated, deliver better glycemic
controlandlesshypoglycemiathanNPH-
based basal-bolus treatments, and al-
though this has not been as clearly
demonstrated as with analogs, pumps
certainly offer an effective approach in re-
ducing blood glucose, which Bode char-
acterized as simple to administer and
discrete. The promise of the patch pumps
described by Bohanon is to further im-
prove this approach to insulin adminis-
tration for type 2 diabetes and to be cost
effective,withcomparableexpensetothat
of current insulin analogs. For subjects
requiringlargeinsulindoses,U-500insu-
lin has been used successfully in pumps
(6), although one should be careful of the
potentialforocclusionoftheveryconcen-
trated insulin in the tubing. Medicare al-
ready reimburses use of current insulin
pumps for subjects with A1C above goal,
frequent hypoglycemia or hypoglycemia
unawareness, the need for a ﬂexible insu-
lin regimen, and C-peptide and insulin
autoimmunity requirements.
Bode reviewed a number of studies
comparing insulin pump with MDI,
whicharesummarizedinTable1andcer-
tainly show feasibility of this approach,
although not demonstrating superiority
to MDI.
Bode concluded that insulin pump
treatment “clearly improves glucose con-
trol with a simple regimen, improves
qualityoflifeandsatisfaction,andmaybe
the preferred therapy for type 2 [diabetic]
patients not at goal.” He suggested that
randomized controlled trials of subjects
failing to achieve control on MDI were
neededtobetterunderstandwhichtype2
diabetic subjects are appropriate candi-
dates for the approach, that ongoing as-
certainment of cost-effectiveness will be
important, and that the development of
simple and easy-to-use pumps will be of
great importance in allowing greater use
of this technology.
AwidevarietyofapproachestoCGM,
pump insulin treatment, and subcutane-
ousinsulinwerepresentedatthemeeting.
A16-weekpilotstudyinwhichBodepar-
ticipated was presented by Edelman et al.
(abstract 428) describing 58 type 2 dia-
betic patients taken off oral medications
other than metformin, placed on CSII be-
ginning with a single basal dose, with
70% remaining on this and 18% con-
trolled with two basal rates. Although not
a controlled study, the observation that
57-year-old patients with duration of di-
abetes 13 years showed a reduction in
A1C from 8.4 to 7.2% was of interest.
Body weight increased on average by 1.9
kg, but there was no weight gain in those
not previously on insulin, perhaps be-
cause 44% of them had received a thiazo-
lidinedione. Hypoglycemia occurred in
59% of patients, although there were no
severe episodes.
Studies of CSII
Anumberoffurtherstudiesdescribedap-
proaches relevant to CSII. Heinemann et
al. (abstract 230) infused insulin lispro
with CSII at 0.5, 1.0, and 2.0 units/h for
4 h periods in 10 type 1 diabetic men and
found that the glucose infusion rate re-
quired to maintain euglycemia increased
progressively over each period. The re-
searchers suggested that the typical ma-
neuver of reducing basal insulin infusion
rates often recommended for exercise or
low glucose levels may not, then, rapidly
lead to desired effects. Recognizing this
prolonged effect of subcutaneous insulin
delivered by CSII, Castle et al. (abstract
207) reported reduction in late postpran-
dial hypoglycemia with automated low-
dose glucagon delivery using a closed
loop algorithm determining insulin and
glucagonratesbasedonthedifferencebe-
tween glucose and target level and the
glucose rate of change. Russell et al. (ab-
stract 235) similarly reported use of glu-
cagon administration in reducing
hypoglycemia in CSII, although they
noted that subjects with prolonged dura-
tion of action of insulin lispro failed to
show the effect with the algorithm used,
suggesting that a change in model param-
eters might be required in such cases. Ko-
vatchev et al. (abstract 228) studied a
different approach to mitigate the time
lags of CGM and subcutaneous insulin
delivery, using model-predictive control
algorithmsandreportingaﬁvefoldreduc-
tion in hypoglycemic incidents while in-
creasing the time spent within the 3.9–
7.8 mmol/l range.
Rodbardetal.(abstract208)reported
reduced frequency of hyperglycemia in
Table 1—Controlled trials of CSII for type 2 diabetes
Reference Number of patients Beneﬁt of pump
7 20 randomized to MDI vs. CSII 3/10 achieved goal GHb with MDI, 8/10
with CSII (signiﬁcant difference)
8 132 randomized to MDI
(aspart/NPH insulin) vs. CSII
A1C 8.237.6% pump, 837.5% MDI
(not a signiﬁcant difference); lower am
postmeal glucose with CSII, trend at
other meals, 93% preferred pump
9 53 CSII vs. 54 MDI for 52
weeks
A1C 8.436.6% with MDI vs. 8.136.4%
with CSII (not a signiﬁcant difference)
10 17-person crossover trial
(NPH insulin plus lispro
three times daily vs. CSII)
A1C 9.0%, decreased to 8.6% with MDI
and 7.7% with CSII (signiﬁcant)
11 40-person crossover trial No signiﬁcant difference in A1C
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notviewingresultsoftheirCGM,andJen-
kinsetal.(abstract209)showedthattype
1 diabetic adults but not adolescents had
improvement in A1C when initiated to
CGM along with an algorithm guiding
their responses, but not when the algo-
rithm was begun 16 weeks after the
beginning of CGM. Weinzimer et al. (ab-
stract 211) reported that, with four visits
and a follow-up telephone call over 6
months, type 1 diabetic subjects using
CGM had a 0.2% reduction in A1C when
monitoring at least 6 days weekly, but a
0.1%increasewithlessfrequentmonitor-
ing. Raccah et al. (abstract 205) reported
that type 1 diabetic subjects using com-
bined CSII/CGM had a reduction in A1C
from 9.4 to 8.3%, whereas those on CSII
with conventional capillary glucose self-
monitoring had a reduction in A1C from
9.3 to 8.7%. Hovorka et al. (abstract 206)
found that during 88 overnight inpatient
closed loop studies with an interacting
multiple-model strategy to process glu-
cose versus CSII alone in 17 type 1 dia-
beticyouthandadults,hypoglycemiawas
reduced with 7 vs. 20% of overnight glu-
cose levels 70 mg/dl, whereas time at
target was increased with 66 vs. 38% of
glucose levels 70–144 mg/dl.
Bragd et al. (abstract 229) reported
that 15 CSII-treated type 1 diabetic pa-
tients randomized to glargine versus CSII
had 0.3% lower A1C and 1.2 mmol/l
lower mean CGM over 4 weeks with the
latter,althoughglucosevariabilitydidnot
change; the nonblinded study protocol
and prior CSII use may have inﬂuenced
these results. Noh et al. (abstract 231)
studied a 6-month period of CSII in 33
type 2 diabetic subjects with mean A1C
9.1% and reported reduction in A1C to
6.7%, with an 88% increase in endoge-
nous insulin secretion (30-min change in
insulin/change in glucose) and 43% re-
duction in the 120-min proinsulin-
insulin ratio following a mixed meal; it is
unlikely, however, that CSII per se was
responsible for this improvement.
Prandial insulin treatment
Folkersen et al. (abstract 467) analyzed
determinants of treatment effect of pran-
dial insulin lispro versus basal insulin
NPH or glargine in 594 subjects partici-
patingintheHyperglycemiaanditsEffect
after Acute myocardial infarction on
caRdiovascular outcomes in patients with
Type 2 diabetes (HEART2D) study, ﬁnd-
ing that those with lower baseline A1C
were more likely to reach a level 7%,
whereas those with higher baseline A1C
were more likely to achieve an A1C re-
duction 0.3%; treatment group was not
asigniﬁcantpredictorofglycemicchange.
Similarly, Riddle et al. (abstract 468) re-
ported an analysis of 12 studies of 2,193
subjects treated by structured titration
with insulin glargine and found that with
baseline A1C 8, 8–8.4, 8.5–8.9,
9–9.4, and 9.5%, A1C decreased by
progressively greater amounts of 0.9, 1.4,
1.6, 2.0, and 2.6%, but to progressively
higher levels of 6.7, 6.8, 7.1, 7.2, and
7.6%, respectively. Further evidence of
the importance of baseline glycemia was
reported by Peters et al. (abstract 568)
from a database of 181 type 2 diabetic
subjects receiving insulin glargine with
lispro three times daily before meals, 104
receiving glargine alone, and 196 and
448, respectively, receiving biphasic in-
sulin lispro three times or twice daily. For
all groups, lower A1C levels prior to the
conclusion of the 16- to 24-week studies
predicted the ability to achieve target lev-
els 7%, interestingly with higher body
weightalsopredictingsuccessinglycemic
control.
Cengiz et al. (abstract 19) performed
euglycemic glucose clamps in seven type
1 diabetic youth after administering
glargine and lispro insulin 0.4 and 0.2
units/kg body wt either as separate injec-
tions or mixed and found that mixing vir-
tually abolished the lispro effect and
should not be recommended.
Raman et al. (abstract 20) adminis-
tered prandial insulin alone or at a 20%
lower dosage with exenatide (1.25 or 2.5
g) to eight type 1 diabetic adolescents
prior to a standard breakfast and found
90% reduction in glucose excursions
over the subsequent 2 h, without gluca-
gon suppression, but with delay in gastric
emptying, suggesting that this agent may
play a role in both types of diabetes.
Karounos et al. (abstract 118) compared
prandial administration of a rapid-acting
insulin analog or pramlintide in 112 type
2 diabetic patients who were receiving
basal insulin and reported 1.1 vs. 0.9%
reduction in A1C, but 4.2 kg weight gain
vs. 0.3 kg weight loss, with greater hypo-
glycemia frequency in the insulin-treated
group. Those failing to achieve A1C
6.5% at 24 weeks were given both
pramlintide or prandial insulin in combi-
nation, with little evidence of additional
beneﬁt over the succeeding 12 weeks.
Strojek et al. (abstract 546) treated
480 insulin-naïve subjects with biphasic
insulinaspartbeforedinnerversusinsulin
glargine at bedtime, both in combination
with metformin and glimepiride, and
demonstrated that A1C decreased from
8.5% to a signiﬁcantly greater extent with
biphasic insulin (by 1.4 vs. 1.3%), but
that nocturnal hypoglycemia occurred
1.1 vs. 0.5 times yearly; weight increased
1.7 kg with both agents. Vora et al. (ab-
stract 451) compared 310 type 2 diabetic
patients receiving metformin plus either
biphasic insulin aspart twice daily or in-
sulin glargine once daily plus insulin glu-
lisinethreetimesdailybeforemealsfor52
weeks and reported A1C reductions of
0.8 vs. 1.3%. Although the latter regimen
was27%morecostly,principallybecause
of the cost of more frequent capillary glu-
cose monitoring, per unit A1C lowering
there were cost savings of 23%.
Owens et al. (abstract 458) treated
135 type 2 diabetic subjects with insulin
glargine and oral agents, titrating to fast-
ing glucose 100 mg/dl. A total of 106
subjects failed to achieve A1C 7% at 3
months (mean 7.9%) and were random-
ized to addition of insulin glulisine prior
tothemainmealortocontinuationoforal
agents plus glargine alone, with the single
prandial insulin dose leading to improve-
ment in A1C and mean glucose without
greater weight gain or more frequent hy-
poglycemia. Davidson et al. (abstract
496) presented information on a study of
343 subjects who failed to achieve ade-
quate control with glargine plus orals af-
ter 14 weeks and who were randomized
toadditionofinsulinglulisinebeforeone,
two, or all three meals for 24 weeks, re-
ducing A1C from 7.9 to 7.4, 7.4, and
7.3%, respectively, with similar changes
in body weight, although with a trend for
more frequent hypoglycemia with the
greater number of insulin doses. Rosen-
stock et al. (abstract 466) performed a
similar study comparing 654 type 2 dia-
beticpatientsrandomizedtoglargineplus
Technosphereinsulinforprandialcontrol
versus biphasic insulin aspart twice daily
and found, however, A1C reductions of
0.6 vs. 0.7% over 52 weeks from baseline
of 8.7%, although with 0.8 vs. 2.4 kg
weight gain and with 48 vs. 69% mild-to-
moderate and 4 vs. 10% severe hypogly-
cemia, respectively. Bergenstal et al.
(abstract 478) randomized 565 glargine-
treatedtype1diabeticpatientstoprandial
administration of Technosphere insulin
versus a rapid-acting insulin analog and
reported 0.2 vs. 0.5% A1C reduction, but
greater reduction in fasting and in 1-h
postprandial glucose levels and 0.5 kg
weight loss vs. 1.4 kg weight gain. Given
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ingthattheinjectedanalogwasassociated
with a somewhat greater frequency of
hypoglycemia.
Potocka et al. (abstract 232) com-
paredTechnosphereandExuberainhaled
insulin with insulin lispro prior to a stan-
dardizedmealin18insulin-treatedtype2
diabetic subjects and found that the nadir
of endogenous glucose production oc-
curred at 40, 130, and 75 min with the
three preparations, suggesting the former
tohavepotentialbeneﬁtinreducingpost-
prandial hyperglycemia, although total
postprandial glucose excursion and sup-
pression of glucose production were sim-
ilar. Amin et al. (abstract 570) studied
pulmonary function in 730 diabetic sub-
jects receiving Technosphere insulin and
824 using other treatments. Mean levels
of the forced expiratory volume in 1 s
were signiﬁcantly lower with the inhaled
preparation, and there was a trend to
lower pulmonary diffusing capacity. The
investigatorsmaybereducingevidenceof
adverse effect by giving mean levels of
these parameters; the frequency of reduc-
tion in these parameters by, say, 25% or
someotherclinicallyrelevantamountwas
not presented. Palermo et al. (abstract
233) showed that administration of 12
units of a buccal spray insulin (Generex
Oral-lyn) reduced blood glucose levels
following 75 g oral glucose in 15 subjects
with impaired glucose tolerance. Geho et
al. (abstract 424), Kidron et al. (abstract
434), and Iyer (abstract 442) described
studies of orally administered insulin
preparations in type 2 diabetic patients,
showing effective glucose lowering.
Rys et al. (abstract 449) reported a
meta-analysisof12trialsof3,553diabetic
subjectsrandomizedtoinsulinaspartver-
sus regular human insulin, showing a
0.1% reduction in A1C and reductions in
glucose levels after breakfast, lunch, and
dinner by 26, 20, and 15 mg/dl, respec-
tively, with a one-third lower rate of
nocturnal hypoglycemia. Heller et al. (ab-
stract 505) reported a similar analysis of
10 trials of 3,727 diabetic subjects receiv-
ing NPH insulin with either regular
human insulin or insulin aspart and con-
ﬁrmed the ﬁndings of 0.1% lower A1C,
lower postprandial glucose levels, and re-
duction in nocturnal hypoglycemia. Bo-
ron et al. (abstract 513) randomized 180
hospitalized subjects treated with insulin
glargine at bedtime to receive either hu-
man insulin or insulin glulisine three
times daily before meals and reported 6,
7,and13mg/dllowermean,preprandial,
and postprandial glucose with glulisine,
the difference increasing with duration of
treatment, so that mean preprandial glu-
cose levels averaged 160 vs. 131 mg/dl
after 7 days. Hypoglycemia rates were
similar. Arnolds et al. (abstract 528) per-
formed euglycemic clamp studies in 12
nondiabetic subjects after administration
of 0.2 units/kg of insulin aspart versus
glulisine and found the glucose infusion
during initial 30 min after administration
to be approximately twice as great with
the latter, although the time of maximal
insulin effect was identical at 90 min with
both products. Bolli et al. (abstract 555)
randomized37obesetype2diabeticsub-
jects to 0.2 units/kg insulin aspart versus
glulisine prior to a test meal, ﬁnding glu-
cose peaks of 181 vs. 170 mg/dl.
Basal insulin treatment
Hohberg et al. (abstract 448) adminis-
tered metformin with either NPH or
glargine insulin endeavoring to obtain
fasting glucose 100 mg/dl to 28 type 2
diabetic patients, showing that with fast-
ing glucose reduced from 158 to 120 mg/
dl, postprandial proinsulin release was
similarly reduced with both insulin treat-
ments, but glargine was more effective af-
ter the evening meal in reducing
proinsulin levels. Liebl (abstract 524)
treated 204 previously insulin-naı ¨ve type
2 diabetic patients receiving metformin
andmealtimerepaglinidewithinsulinde-
temir versus NPH, showing 1 kg weight
loss versus 1 kg weight gain with reduc-
tion in systolic blood pressure and in-
crease in HDL in the former group,
although A1C reduction was similar at
1.8 vs 1.6% from baseline levels around
8.7%.
Fonseca et al. (abstract 23LB) ana-
lyzed a medication and diagnosis data-
base for 10,667 versus 2,009 oral agent–
treated type 2 diabetic subjects receiving
glargine versus NPH insulin and found
evidence of fewer microvascular events in
the former group after adjusting for base-
line differences in age, A1C, sex, and co-
morbidities. Lee et al. (abstract 576)
compared the effect of adding glargine
versus NPH insulin to oral agents in a
combined analysis of four trials, compar-
ing outcome in 1,690 subjects aged 65
and in 441 subjects aged 65, conﬁrm-
ing a lower rate of nocturnal hypoglyce-
mia in the older group, and also ﬁnding
thatA1Cdecreased1.2%withglarginevs.
0.9% with NPH insulin in the older pa-
tients. Thibaudeau et al. (abstract 435)
described studies with recombinant insu-
lin covalently conjugated to Cys34 of re-
combinant human albumin, showing
longer biological activity than insulin
glargine in a diabetic rat model, suggest-
ing that this form of insulin might require
administration less often than once daily.
Dailey et al. (abstract 480) performed
a meta-analysis of 20 studies of insulin
glargine and 4 studies of insulin detemir.
A1C decreased 1.4% with both agents,
and weight increased 2.3 vs. 1.7 kg, an
insigniﬁcant difference, although the ad-
ministered insulin dose was signiﬁcantly
less with glargine at 37 vs. 52 units daily.
Half of the detemir-treated patients re-
quired twice-daily dosing.
In innovative studies using CGM, im-
provement in glycemia was reported by
Rong et al. (abstract 443) in insulin-
treated diabetic patients who were ad-
ministered acarbose and by Matsuura et
al.(abstract492)inpatientswhoreceived
detemir or glargine insulin monotherapy
with addition of miglitol. Chun et al. (ab-
stract450)treatedtype2diabeticsubjects
with insulin glargine titrated to fasting
glucose120mg/dl;75patientsreceived
a meglitinide plus -glucosidase inhibi-
tor, whereas 53 received glargine with a
sulfonylurea plus metformin. A1C levels
decreased from 8.9 to 8.0 vs. 8.5%, and
despite similar premeal glucose of 116 vs.
128 mg/dl, mean postprandial glucose
was209vs.255mg/dl,suggestingbeneﬁt
of targeting postprandial glycemia.
Further studies of insulin treatment
Boothe et al. (abstract 5LB) produced re-
combinant human insulin from trans-
genic safﬂower plants and reported that
insulin could be puriﬁed from the seeds
and administered both in animals and in
23 healthy volunteers with bioequiva-
lence to Humulin R. Kreugel et al. (ab-
stract 440) randomized 130 obese
insulin-treated diabetic subjects in a
crossover trial with 5 mm  31G needles
v s .8m m 31G needles and found sim-
ilar A1C over 3 months and similar pa-
tient preference, without difference in
hypoglycemic events, bruising, or pain.
There was less bleeding with the shorter
and less insulin leakage with the longer
length needles.
Retnakaran et al. (abstract 494) treated
34type2diabeticsubjectswithA1C7%on
zerototwooralagentswithinsulindetemir
pluspremealaspartfor4–8weeks,exam-
ininga4-hmealtestbeforeand1dayafter
the completion of the intensive treatment
protocol. Twenty-three patients had fast-
ing glucose 126 mg/dl before the meal
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peptide levels through the meal test than
those failing to achieve normal fasting
glucose, suggesting that even with
apparently adequate glycemic control
there is clinically important glucose
toxicity. Li et al. (abstract 499) random-
ized 382 newly diagnosed type 2 diabetic
patients to intensive insulin treatment ver-
susthesulfonylureagliclazide,withorwith-
out metformin, with treatment stopped
after 2 weeks of euglycemia, and reported
thatinsulintreatmentprolongedthetimein
glycemic remission.
Milleretal.(abstract629)reportedpre-
dictors of hypoglycemia in a nationally
linked database of 1.38 million Veterans
Administration diabetic patients followed
from 2000 to 2004, with 2.02 million hy-
poglycemic episodes. Among those receiv-
ing insulin, hypoglycemia occurred 5.8-
and 7.3-fold more often, respectively, with
historiesofpriorhypoglycemiaandofprior
ketoacidosis or hyperglycemic coma,
whereas in those not receiving insulin the
respective risk increases were 10- and 14-
fold greater. Other risk factors, associated
with 1.1- to 1.4-fold increases in hypogly-
cemia in both treatment groups, were
historyofamputation,retinopathy,neurop-
athy, renal disease, peripheral arterial dis-
ease, and recent hospitalization.
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